Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Century Therapeutics Inc (NQ: IPSC )

3.030 -0.160 (-5.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,162
Open 3.240
Bid (Size) 3.030 (11)
Ask (Size) 3.360 (2)
Prev. Close 3.190
Today's Range 3.010 - 3.355
52wk Range 2.805 - 14.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Century Therapeutics: Q1 Earnings Insights
 
Via Benzinga
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-39.03%
-39.03%
1 Month
-3.19%
-3.19%
3 Month
-33.26%
-33.26%
6 Month
-70.72%
-70.72%
1 Year
-65.13%
-65.13%

More News

Read More
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Century Therapeutics
Via Benzinga
Century Therapeutics Announces Leadership Changes
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics's Return On Capital Employed Overview
Via Benzinga
Where Century Therapeutics Stands With Analysts
Via Benzinga
8 Analysts Have This to Say About Century Therapeutics
Via Benzinga
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the AACR Annual Meeting 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022
Via Benzinga
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
5 Health Care Stocks That Are Diving - And May Rally
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Top 5 Health Care Stocks That May Surge
Via Benzinga
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
Via InvestorPlace
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
Via Benzinga
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.